AZN catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 3NCT05261399Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have...AstraZeneca · CarcinomaActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jul 6, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT04068610COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRCMedImmune LLC · Metastatic Microsatellite-stable Colorectal CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Oct 10, 2022Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT02546661Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerAstraZeneca · Muscle Invasive Bladder CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Mar 18, 2020Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT04157348Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.AstraZeneca · Eosinophilic Granulomatous VasculitisActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Aug 10, 2023Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT04999969Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or...AstraZeneca · Locally Advanced or Metastatic Solid TumoursActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Oct 7, 2024Actual
- Interventions
- Locked
- Completion LockedNo phase registeredNCT05456867A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice...AstraZeneca · NSCLC, Non-small-cell Lung CarcinomaActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07218172Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)AstraZeneca · Severe AsthmaActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT04745689Study of AZD2811 + Durvalumab in ES-SCLCAstraZeneca · Small-Cell Lung CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jun 18, 2022Actual
- Interventions
- Locked
- Completion LockedNo phase registeredNCT05817110Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.AstraZeneca · Lung MalignancyActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Dec 6, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06724809Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSDAlexion Pharmaceuticals, Inc. · NMOSDActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Dec 7, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT07222917A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in...AstraZeneca · Chronic Kidney Disease and HypertensionActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Dec 10, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06712563Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care SettingAstraZeneca · Pulmonary Disease, Chronic ObstructiveActive, not recruitingAZNLeadIQVCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 14, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT02519348A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced...MedImmune LLC · Hepatocellular CarcinomaActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Nov 6, 2020Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT03737643Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib...AstraZeneca · Advanced Ovarian CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Mar 17, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT05692180A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and...AstraZeneca · AsthmaActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Dec 23, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT07128615A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)AstraZeneca · Influenza AActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jan 28, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT02264678Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer AgentsAstraZeneca · Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Mar 4, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT05883644Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)AstraZeneca · Advanced Hepatocellular CarcinomaActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Mar 30, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT00099437Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer...AstraZeneca · Breast CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Feb 27, 2009Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT00750841Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid TumoursAstraZeneca · Solid TumorsActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jul 30, 2009Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT01081951Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With...AstraZeneca · Ovarian CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Oct 10, 2011Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT01874353Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyAstraZeneca · Platinum SensitiveActive, not recruitingAZNLeadMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Sep 19, 2016Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT01933932Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat...AstraZeneca · Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jun 7, 2016Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT02143466AZD9291 in Combination With Ascending Doses of Novel TherapeuticsAstraZeneca · Advanced Non Small Cell Lung CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Mar 4, 2020Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT02180724An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström MacroglobulinemiaAcerta Pharma BV · Waldenström Macroglobulinemia (WM)Active, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Oct 1, 2019Actual
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 31 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.